# 28bio, Inc.: Form D capital raise (Metairie, LA)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 70/100
**Estimated post-raise budget for this service type:** $170,499 (heuristic)

| Field | Value |
|---|---|
| Industry | Biotechnology (Healthcare & Life Sciences) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $8,524,945 |
| Total offering | $8,524,945 |
| Investors so far | 10 |
| First sale | 2025-05-21 |
| Filed | 2026-10-29 (amendment) |
| Entity | Corporation |

## Executives and related persons (as listed in the filing)
- Alif Saleh: Executive Officer, Director
- David Weiner: Director
- Dale Pfost: Director
- Michael Katz: Director
- Miklos Kobor: Director
- Paul Friel: Director

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $8,524,945 so far.
- Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.
- Filed 7 days ago.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/1769360/000176936026000003/). Last refreshed: 2026-11-04T15:17:01.911Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.